Quantcast

Pharma news

NICE backs EUSA Pharma’s Qarziba for children with high-risk neuroblastoma

The National Institute for Health and Care Excellence (NICE) has recommended the use of the  EUSA Pharma’s targeted cancer immunotherapy, QARZIBA

Posted in Approval, news | Tagged , | Leave a comment

Myocant Sciences complets screening patients for heavy menstrual bleeding study

Myovant Sciences has completed screening patients for its LIBERTY 1 study, the first of two Phase 3 replicate studies evaluating

Posted in Approval, news | Tagged | Leave a comment

Alvogen, Prestige BioPharma in Hervelous selling deal for Central and Eastern Europe

Alvogen and Prestige BioPharma have entered into a deal for the exclusive partnership and supply for the commercialization of Prestige

Posted in Approval, news | Tagged , | Leave a comment

AstraZeneca’s lung cancer drug approved in Japan

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and

Posted in Approval, news | Leave a comment

CHMP recommends approval of Sanofi’s Cablivi

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe

Posted in Approval, news | Tagged , , , , | Leave a comment

Novartis aims at spinoff of Alcon eye care devices business

Novartis on Friday said it intends to spinoff Alcon, its eye care division, into a separately-traded standalone company, which would

Posted in Approval, news | Tagged , | Leave a comment

Sanofi and Advent in negotiations for €1.9 billion acquisition of Zentiva

Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the

Posted in Approval, news | Tagged , , | Leave a comment

Better prevention can curbe significant disruption to daily life and work caused by migraine

Novartis and the European Migraine and Headache Alliance (EMHA) Wednesday presented initial findings from the largest global migraine patient study

Posted in Approval, My Pharmaceutical, news | Leave a comment

Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer

AstraZeneca and Merck’s Phase III SOLO-1 trial of Lynparza (olaparib) tablets, for women with BRCA-mutated (BRCAm) advanced ovarian cancer treated

Posted in Approval, news | Tagged , , , | Leave a comment

Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market

Symcel said Wednesday it has appointed two new board members; Erik Walldén and Stefan Löfås, who are expected to play a

Posted in Approval, news | Tagged | Leave a comment